Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

mRNA-based respiratory syncytial virus vaccine - GlaxoSmithKline

Next Previous
X
Search
Drug Profile

mRNA-based respiratory syncytial virus vaccine - GlaxoSmithKline

Latest Information Update: 18 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GSK
  • Class Respiratory syncytial virus vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 30 Sep 2024 Phase-I clinical trials in Respiratory syncytial virus infections in Spain, Spain, Australia, USA (IM) (NCT06573281) (EudraCT2024-512846-41)
  • 03 Sep 2024 Preclinical trials in Respiratory syncytial virus infections in United Kingdom (IM) (NCT06573281)
  • 27 Aug 2024 GlaxoSmithKline plans to initiate a phase I trial for Respiratory Syncytial Virus Infections (Preventions) in the US, Australia and Spain (IM) (NCT06573281)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top